8-K: Intellia Therapeutics Announces Positive Two-Year Data for Nexiguran Ziclumeran (nex-z) in ATTR Amyloidosis Patients

Intellia Therapeutics reports positive two-year follow-up data from its Phase 1 study of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy, showing sustained TTR reductions and clinical improvements.

Summary

• Intellia Therapeutics announced positive two-year follow-up data from the Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
• The data, presented at the Peripheral Nerve Society Annual Meeting, showed sustained reductions in transthyretin (TTR) levels and clinical improvements in patients.
• Patients receiving a one-time dose of 0.3 mg/kg or higher of nex-z (n=33) experienced a mean serum TTR reduction of 90% by Day 28, with levels remaining stable for at least 24 months.
• Among 18 patients with mNIS+7 assessment at 24 months, 14 showed a clinically meaningful improvement of 4 points, including 5 of 6 patients previously progressing on patisiran.
• Nex-z was generally well tolerated, with mild to moderate infusion-related reactions being the most common adverse events.
• Enrollment in the Phase 3 MAGNITUDE-2 study for ATTRv-PN is progressing well, with a potential BLA submission targeted for 2028.
• The Phase 3 MAGNITUDE study for ATTR-CM is currently enrolling, with completion expected by early 2027.

Sentiment

Score: 8

Explanation: The document presents positive clinical data, indicating potential for a successful therapy. The sentiment is optimistic due to the sustained TTR reductions and clinical improvements observed in the study.

Positives

• Nex-z demonstrates deep, durable, and consistent reductions in serum TTR levels.
• Clinically meaningful improvements were observed in ATTRv-PN related outcomes at 24 months compared to baseline.
• Improvements were seen even in patients who were previously progressing on patisiran.
• Nex-z has shown a generally favorable safety and tolerability profile.
• Enrollment in the MAGNITUDE-2 study is progressing well.

Negatives

• The most commonly reported treatment-related adverse events were infusion-related reactions, although they were mild or moderate and did not lead to discontinuations.
• Observed liver enzyme abnormalities were reported, but were not considered serious, were asymptomatic, and resolved spontaneously.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include those related to intellectual property, regulatory approvals, clinical trial enrollment and success, and reliance on collaborations.

Future Outlook

Intellia expects to support a potential biologics license application submission for nex-z for the treatment of ATTRv-PN by 2028 and anticipates completing enrollment of the pivotal Phase 3 MAGNITUDE study for ATTR amyloidosis with cardiomyopathy by early 2027.

Management Comments

• Intellia President and CEO John Leonard, M.D., stated that the data supports the hypothesis that deep reductions in TTR levels may lead to improved outcomes in ATTR amyloidosis.
• He also noted that the data is the first to show improvement in patients who had previously progressed on patisiran.

Industry Context

This announcement positions Intellia as a leading company in the development of CRISPR-based therapies for ATTR amyloidosis, competing with existing treatments like patisiran and potentially offering a one-time treatment option.

Comparison to Industry Standards

• Patisiran (Onpattro) from Alnylam Pharmaceuticals is an RNAi therapeutic that requires ongoing infusions, while nex-z aims to provide a one-time treatment.
• Other companies like Ionis Pharmaceuticals are also developing treatments for ATTR amyloidosis, but Intellia's CRISPR-based approach offers a unique mechanism of action.
• The 90% mean serum TTR reduction achieved by nex-z is comparable to or better than results seen with other ATTR therapies.

Stakeholder Impact

• Positive results could lead to a new treatment option for patients with ATTR amyloidosis.
• Successful development and commercialization of nex-z could increase shareholder value.
• Employees may benefit from the company's progress and potential growth.

Next Steps

• Continue enrollment in the Phase 3 MAGNITUDE-2 study for ATTRv-PN.
• Continue enrollment in the Phase 3 MAGNITUDE study for ATTR-CM.
• Prepare for a potential BLA submission for nex-z for the treatment of ATTRv-PN by 2028.

Key Dates

Keywords

nexiguran ziclumeran, NTLA-2001, ATTR amyloidosis, CRISPR, gene editing, Intellia Therapeutics, Regeneron, ATTRv-PN, MAGNITUDE-2, clinical trial